Immix Biopharma highlights NXC-201 CAR-T data in relapsed/refractory AL amyloidosis trial presentation
IMMX•IMMX•IMMX•IMMX•NEXICART-2 is an open-label, single-arm, multi-site phase 1/2 study with 45 patients; enrollment was completed in March 2026.
The program timeline calls for a planned BLA submission following 1-year follow-up for all 45 patients, with the next update in late September 2026.
The commercial launch plan targets the end of 2027, and the presentation cites expected pricing of USD 588K, referencing 2026 Carvykti BCMA CAR-T pricing.
Immix Biopharma highlighted NXC-201 BCMA CAR-T in relapsed/refractory AL amyloidosis, a setting with no FDA-approved therapies.
NXC-201 posted a 95% complete hematologic response rate in NEXICART-2 data presented at ASH 2025, with a May 2026 update.
